BACKGROUND: Therapeutic drug monitoring (TDM) of infliximab (IFX) trough levels and anti-drug antibodies in conjunction with symptoms, disease history, and investigations can aid decision-making. This study evaluated 1-year outcomes of patients with decisions that were altered on the basis of TDM results, in order to investigate whether outcomes from TDM-based decisions to adjust or stop IFX treatment are durable. METHODS: We retrospectively collected clinical outcomes 12 months post treatment decisions based on proactive TDM. Patients whose initial treatment decisions were altered on the basis of TDM results were compared with those where the decision remained unchanged. Events of interest were inpatient admissions with active inflammatory bowel disease (IBD), further changes to biologic therapy, and IBD-related health-care costs. RESULTS: Of 189 patients, 54 (28%) had initial treatment decisions altered in the light of TDM results. The 135 patients whose initial decision was not altered in light of TDM results served as the comparator. There were no differences in hospitalization rates or subsequent biologic switches between the altered decision groups and the comparator group. IBD-related health-care costs were higher in those whose initial decision was altered (median GBP 7,912 vs. GBP 6,521; p < 0.0001) due to higher drug costs (median GBP 7,062 vs. GBP 6,012; p < 0.0001). CONCLUSION: Our study demonstrates good outcomes from changes to IFX treatment based on TDM. Patients with a decision to stop, switch, or continue with an adjusted IFX dose experienced comparable clinical outcomes but had higher drug-related expenditure than those whose treatment decision was not altered in light of TDM.
BACKGROUND: Therapeutic drug monitoring (TDM) of infliximab (IFX) trough levels and anti-drug antibodies in conjunction with symptoms, disease history, and investigations can aid decision-making. This study evaluated 1-year outcomes of patients with decisions that were altered on the basis of TDM results, in order to investigate whether outcomes from TDM-based decisions to adjust or stop IFX treatment are durable. METHODS: We retrospectively collected clinical outcomes 12 months post treatment decisions based on proactive TDM. Patients whose initial treatment decisions were altered on the basis of TDM results were compared with those where the decision remained unchanged. Events of interest were inpatient admissions with active inflammatory bowel disease (IBD), further changes to biologic therapy, and IBD-related health-care costs. RESULTS: Of 189 patients, 54 (28%) had initial treatment decisions altered in the light of TDM results. The 135 patients whose initial decision was not altered in light of TDM results served as the comparator. There were no differences in hospitalization rates or subsequent biologic switches between the altered decision groups and the comparator group. IBD-related health-care costs were higher in those whose initial decision was altered (median GBP 7,912 vs. GBP 6,521; p < 0.0001) due to higher drug costs (median GBP 7,062 vs. GBP 6,012; p < 0.0001). CONCLUSION: Our study demonstrates good outcomes from changes to IFX treatment based on TDM. Patients with a decision to stop, switch, or continue with an adjusted IFX dose experienced comparable clinical outcomes but had higher drug-related expenditure than those whose treatment decision was not altered in light of TDM.
Authors: Niels Vande Casteele; Marc Ferrante; Gert Van Assche; Vera Ballet; Griet Compernolle; Kristel Van Steen; Steven Simoens; Paul Rutgeerts; Ann Gils; Séverine Vermeire Journal: Gastroenterology Date: 2015-02-24 Impact factor: 22.682
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: Nicholas A Kennedy; Graham A Heap; Harry D Green; Benjamin Hamilton; Claire Bewshea; Gareth J Walker; Amanda Thomas; Rachel Nice; Mandy H Perry; Sonia Bouri; Neil Chanchlani; Neel M Heerasing; Peter Hendy; Simeng Lin; Daniel R Gaya; J R Fraser Cummings; Christian P Selinger; Charlie W Lees; Ailsa L Hart; Miles Parkes; Shaji Sebastian; John C Mansfield; Peter M Irving; James Lindsay; Richard K Russell; Timothy J McDonald; Dermot McGovern; James R Goodhand; Tariq Ahmad Journal: Lancet Gastroenterol Hepatol Date: 2019-02-27
Authors: Byron P Vaughn; Manuel Martinez-Vazquez; Vilas R Patwardhan; Alan C Moss; William J Sandborn; Adam S Cheifetz Journal: Inflamm Bowel Dis Date: 2014-11 Impact factor: 5.325
Authors: R Khanna; B D Sattin; W Afif; E I Benchimol; E-J Bernard; A Bitton; B Bressler; R N Fedorak; S Ghosh; G R Greenberg; J K Marshall; R Panaccione; E G Seidman; M S Silverberg; A H Steinhart; R Sy; G Van Assche; T D Walters; W J Sandborn; B G Feagan Journal: Aliment Pharmacol Ther Date: 2013-07-14 Impact factor: 8.171
Authors: N Mitrev; N Vande Casteele; C H Seow; J M Andrews; S J Connor; G T Moore; M Barclay; J Begun; R Bryant; W Chan; C Corte; S Ghaly; D A Lemberg; V Kariyawasam; P Lewindon; J Martin; R Mountifield; G Radford-Smith; P Slobodian; M Sparrow; C Toong; D van Langenberg; M G Ward; R W Leong Journal: Aliment Pharmacol Ther Date: 2017-10-13 Impact factor: 8.171
Authors: Lorant Gonczi; Zsuzsanna Vegh; Petra Anna Golovics; Mariann Rutka; Krisztina Barbara Gecse; Renata Bor; Klaudia Farkas; Tamás Szamosi; László Bene; Beáta Gasztonyi; Tünde Kristóf; László Lakatos; Pál Miheller; Károly Palatka; Mária Papp; Árpád Patai; Ágnes Salamon; Gábor Tamás Tóth; Áron Vincze; Edina Biro; Barbara Dorottya Lovasz; Zsuzsanna Kurti; Zoltan Szepes; Tamás Molnár; Péter L Lakatos Journal: J Crohns Colitis Date: 2017-06-01 Impact factor: 9.071